Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 2, 2012, Pages 385-389

  Setshedi, Mashiko ^a   Epstein, David ^a   Winter, Trevor A ^c   Myer, Landon ^a   Watermeyer, Gillian ^a   Hift, Richard ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

6 mercaptopurine; Azathioprine; Immunosuppression; Inflammatory bowel disease; Malignancy; Skin cancer

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CARCINOID; CAUCASIAN; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; KAPOSI SARCOMA; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OVARY TERATOMA; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SARCOMA; SKIN CANCER; SMALL INTESTINE CANCER; STOMACH CANCER; TREATMENT DURATION; UTERINE CERVIX CANCER;

EID: 84856193112     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06865.x     Document Type: Article

References (39)

1. Katz JA. Management of inflammatory bowel disease in adults. J. Dig. Dis. 2007; 8: 65-71.
2. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8.
3. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev. 2000; (2): CD000067.
4. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 2009; (1): CD000067.
5. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. 2000; (2): CD000545.
6. Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig. Dis. Sci. 2008; 53: 1455-61.
7. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2007; (1): CD000478.
8. Gaya SB, Rees AJ, Lechler RI, Williams G, Mason PD. Malignant disease in patients with long-term renal transplants. Transplantation 1995; 59: 1705-9.
9. Sheil AG, Disney AP, Mathew TG, Amiss N, Excell L. Malignancy following renal transplantation. Transplant. Proc. 1992; 24: 1946-7.
10. Baccarani U, Adani GL, Montanaro D etal. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant. Proc. 2006; 38: 1135-7.
11. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77: 574-9.
12. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br. J. Dermatol. 2006; 154: 498-504.
13. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J. Am. Acad. Dermatol. 2006; 55: 369-89.
14. Penn I. Incidence and treatment of neoplasia after transplantation. J. Heart Lung Transplant. 1993; 12: S328-36.
15. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J. Rheumatol. 1999; 26: 1705-14.
16. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am. J. Med. 1985; 78: 44-9.
17. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br. Med. J. 1979; 2: 1461-6.
18. Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br. Med. Bull. 2006; 79-80: 153-70.
19. Swann PF, Waters TR, Moulton DC etal. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-11.
20. Karran P, Offman J, Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 2003; 85: 1149-60.
21. Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metabolites-II. Azathioprine and nitroimidazole metabolites. Photochem. Photobiol. 1986; 43: 257-62.
22. O'Donovan P, Perrett CM, Zhang X etal. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-4.
23. Zhang X, Jeffs G, Ren X etal. Novel DNA lesions generated by the interaction between therapeutic thiopurines and UVA light. DNA Repair 2007; 6: 344-54.
24. Austin AS, Spiller RC. Inflammatory bowel disease, azathioprine and skin cancer: case report and literature review. Eur. J. Gastroenterol. Hepatol. 2001; 13: 193-4.
25. Greenstein AJ, Gennuso R, Sachar DB etal. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985; 56: 2914-21.
26. Mellemkjaer L, Olsen JH, Frisch M, Johansen C, Gridley G, McLaughlin JK. Cancer in patients with ulcerative colitis. Int. J. Cancer 1995; 60: 330-3.
27. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991; 67: 2015-19.
28. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment. Pharmacol. Ther. 2002; 16: 1225-32.
29. Farrell RJ, Ang Y, Kileen P etal. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47: 514-19.
30. Kinlen LJ. Non-Hodgkin's lymphoma after immunosuppressive therapy. Gut 2000; 47: 462-3.
31. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2010; 8: 268-74.
32. Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment. Pharmacol. Ther. 2010; 32: 119-30.
33. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-5.
34. Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann. Pharmacother. 2007; 41: 21-8.
35. Lees CW, Critchley J, Chee N etal. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm. Bowel Dis. 2009; 15: 1621-9.
36. South African National Cancer Association. Summary Statistics of Cancer Diagnosed Histologically in 2001 [Internet]. Johannesburg: South African National Cancer Association; 2010. Cited 29 March 2011. Available from URL:.
37. Intersun Program. Ultraviolet Radiation and the INTERSUN Programme [Internet]. Geneva: World Health Organization; 2011. Cited 29 March 2011. Available from URL:.
38. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
39. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003; 22: 7403-13.